NOVT
Get informed when a big investor buys or sells
+ FollowOvervalued by 78.7% based on the discounted cash flow analysis.
| Market cap | $5.32 Billion |
|---|---|
| Enterprise Value | $4.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.47 |
| Beta | 1.72 |
| Outstanding Shares | 41,009,000 |
| P/E Ratio | 88.55 |
|---|---|
| PEG | 49.51 |
| Price to Sales | 5.63 |
| Price to Book Ratio | 3.61 |
| Enterprise Value to Revenue | 4.75 |
| Enterprise Value to EBIT | 48.24 |
| Enterprise Value to Net Income | 79 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.17 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 1958.31% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 9,600▼ 99.61% |
Holdings and activity of institutional investors.
| Ownership % | 6.13%▼ 104.46% |
|---|---|
| Total Invested | $357.13M▼ 95.14% |
| Investors Holding | 64▼ 344.00% |
No data
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers ('OEMs') a competitive advantage. Novanta combines deep proprietary technology expertise and com...